Windtree Therapeutics is a biotechnology company developing early and late-stage therapies for critical conditions. Its lead product candidate, istaroxime, is a Phase 2 dual-mechanism agent (sodium-potassium ATPase inhibitor and SERCA2a activator) for acute heart failure and cardiogenic shock, holding FDA Fast Track designation. The pipeline also includes preclinical SERCA2a activators, rostafuroxin for genetically associated hypertension, and a preclinical aPKCi inhibitor for oncology. In January 2025, the company launched a strategy to acquire small companies with FDA-approved products to become a revenue-generating biotech.
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-15 | 2024-12-31 | 0001437749-25-012093 | EDGAR | 136K words |
| 2024-04-16 | 2023-12-31 | 0001437749-24-012210 | EDGAR | 124K words |
| 2023-03-31 | 2022-12-31 | 0001437749-23-008864 | EDGAR | 106K words |
| 2022-03-31 | 2021-12-31 | 0001437749-22-007757 | EDGAR | 102K words |
| 2021-03-29 | 2020-12-31 | 0001437749-21-007493 | EDGAR | 100K words |
| 2020-04-03 | 2019-12-31 | 0001437749-20-006970 | EDGAR | 108K words |
| 2019-04-16 | 2018-12-31 | 0001437749-19-007339 | EDGAR | 74K words |
| 2018-04-17 | 2017-12-31 | 0001437749-18-007033 | EDGAR | 78K words |
| 2017-03-31 | 2016-12-31 | 0001437749-17-005788 | EDGAR | 90K words |
| 2016-03-29 | 2015-12-31 | 0001140361-16-059208 | EDGAR | 79K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-19 | 2025-09-30 | 0001437749-25-035751 | EDGAR | 48K words |
| 2025-08-19 | 2025-06-30 | 0001437749-25-027382 | EDGAR | 41K words |
| 2025-05-15 | 2025-03-31 | 0001437749-25-017261 | EDGAR | 35K words |
| 2024-11-26 | 2024-09-30 | 0001437749-24-036277 | EDGAR | 40K words |
| 2024-08-19 | 2024-06-30 | 0001437749-24-027232 | EDGAR | 37K words |
| 2024-05-15 | 2024-03-31 | 0001437749-24-017124 | EDGAR | 27K words |
| 2023-11-09 | 2023-09-30 | 0001437749-23-031246 | EDGAR | 27K words |
| 2023-08-07 | 2023-06-30 | 0001437749-23-022308 | EDGAR | 28K words |
| 2023-05-15 | 2023-03-31 | 0001437749-23-014594 | EDGAR | 26K words |
| 2022-11-14 | 2022-09-30 | 0001437749-22-027036 | EDGAR | 27K words |
| 2022-08-11 | 2022-06-30 | 0001437749-22-020091 | EDGAR | 25K words |
| 2022-05-05 | 2022-03-31 | 0001437749-22-011122 | EDGAR | 22K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-22 | 0001437749-26-024009 | EDGAR | 6K words |
| 2026-01-07 | 0001437749-26-000805 | EDGAR | 0K words |
| 2025-12-02 | 0001437749-25-036665 | EDGAR | 12K words |
| 2025-10-16 | 0001437749-25-031178 | EDGAR | 12K words |
| 2025-10-06 | 0001437749-25-030516 | EDGAR | 3K words |
| 2025-09-08 | 0001437749-25-028578 | EDGAR | 0K words |
| 2025-09-02 | 0001437749-25-028170 | EDGAR | 2K words |
| 2025-08-20 | 0001437749-25-027421 | EDGAR | 1K words |
| 2025-08-08 | 0001437749-25-025762 | EDGAR | 1K words |
| 2025-08-05 | 0001437749-25-024720 | EDGAR | 1K words |
428 total filings indexed. 396 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000946486 |
| Ticker | WINT |
| Exchange | OTC |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/WINT (~200 tokens, structured JSON with cryptographic provenance)